Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.15
ULGX's Cash to Debt is ranked lower than
54% of the 389 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ULGX: 0.15 )
ULGX' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.15

Equity to Asset -0.38
ULGX's Equity to Asset is ranked lower than
58% of the 374 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. ULGX: -0.38 )
ULGX' s 10-Year Equity to Asset Range
Min: -0.38   Max: 0.96
Current: -0.38

-0.38
0.96
F-Score: 2
Z-Score: -18.92
M-Score: -3.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -23.64
ULGX's Operating margin (%) is ranked higher than
52% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. ULGX: -23.64 )
ULGX' s 10-Year Operating margin (%) Range
Min: -1950   Max: 12.1
Current: -23.64

-1950
12.1
Net-margin (%) -25.87
ULGX's Net-margin (%) is ranked higher than
52% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 4.58 vs. ULGX: -25.87 )
ULGX' s 10-Year Net-margin (%) Range
Min: -1900   Max: 21.22
Current: -25.87

-1900
21.22
ROE (%) -1021.90
ULGX's ROE (%) is ranked lower than
59% of the 370 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ULGX: -1021.90 )
ULGX' s 10-Year ROE (%) Range
Min: -1021.9   Max: 13.74
Current: -1021.9

-1021.9
13.74
ROA (%) -34.26
ULGX's ROA (%) is ranked lower than
51% of the 386 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ULGX: -34.26 )
ULGX' s 10-Year ROA (%) Range
Min: -85.22   Max: 12.52
Current: -34.26

-85.22
12.52
ROC (Joel Greenblatt) (%) -169.78
ULGX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 12.53 vs. ULGX: -169.78 )
ULGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -751.25   Max: 64.33
Current: -169.78

-751.25
64.33
Revenue Growth (%) -7.80
ULGX's Revenue Growth (%) is ranked higher than
55% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ULGX: -7.80 )
ULGX' s 10-Year Revenue Growth (%) Range
Min: -20.9   Max: 108
Current: -7.8

-20.9
108
EBITDA Growth (%) 17.00
ULGX's EBITDA Growth (%) is ranked higher than
89% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. ULGX: 17.00 )
ULGX' s 10-Year EBITDA Growth (%) Range
Min: -80.1   Max: 17
Current: 17

-80.1
17
EPS Growth (%) 11.90
ULGX's EPS Growth (%) is ranked higher than
85% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. ULGX: 11.90 )
ULGX' s 10-Year EPS Growth (%) Range
Min: -54.1   Max: 11.9
Current: 11.9

-54.1
11.9
» ULGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ULGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.19
ULGX's P/S is ranked higher than
99% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. ULGX: 0.19 )
ULGX' s 10-Year P/S Range
Min: 0.11   Max: 9.56
Current: 0.19

0.11
9.56
EV-to-EBIT -1.53
ULGX's EV-to-EBIT is ranked lower than
55% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 57.20 vs. ULGX: -1.53 )
ULGX' s 10-Year EV-to-EBIT Range
Min: 14.3   Max: 430.2
Current: -1.53

14.3
430.2
Current Ratio 0.92
ULGX's Current Ratio is ranked lower than
59% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. ULGX: 0.92 )
ULGX' s 10-Year Current Ratio Range
Min: 0.79   Max: 24.53
Current: 0.92

0.79
24.53
Quick Ratio 0.63
ULGX's Quick Ratio is ranked lower than
59% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ULGX: 0.63 )
ULGX' s 10-Year Quick Ratio Range
Min: 0.59   Max: 24.29
Current: 0.63

0.59
24.29

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.15
ULGX's Price/Median PS Value is ranked higher than
99% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ULGX: 0.15 )
ULGX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 135
Current: 0.15

0.17
135
Forward Rate of Return (Yacktman) -88.55
ULGX's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. ULGX: -88.55 )
ULGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.1   Max: -4.3
Current: -88.55

-13.1
-4.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Urologix Inc. was incorporated in Minnesota. The company develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use proprietary technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. It acquired the exclusive worldwide license to the Prostiva RF Therapy System in September 2011. These two technologies are designed to be used by urologists in their offices without placing their patients under general anesthesia. CTT uses a flexible catheter to deliver targeted microwave energy combined with a unique cooling mechanism that protects healthy urethral tissue and enhances patient comfort to provide safe, effective, lasting relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. The proprietary Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. These two proven technologies have slightly different, yet complementary, patient indications and providing them to its urologist customers enables them to treat a wide range of patients in their office.
» More Articles for ULGX

Headlines

Articles On GuruFocus.com
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares Feb 01 2011 
Urologix Inc. Reports Operating Results (10-K) Sep 17 2010 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares Dec 08 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares Dec 07 2009 
Urologix Inc. Reports Operating Results (10-K) Sep 21 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,870 Shares Sep 03 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,635 Shares Aug 31 2009 
Urologix Reports Fiscal 2009 Results Including Sequential Growth in Fourth Quarter Fiscal Year 2009 Aug 25 2009 
Urologix to Host Its Fiscal Year 2009 and Fourth Quarter Conference Call Aug 19 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,495 Shares May 29 2009 

More From Other Websites
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 20 2014
Urologix Reports Fourth Quarter and Fiscal Year 2014 Results Aug 19 2014
Urologix Inc Earnings Call scheduled for 5:00 pm ET today Aug 19 2014
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 19 2014
Urologix Reports Fourth Quarter and Fiscal Year 2014 Results Aug 19 2014
Q4 2014 Urologix Inc Earnings Release - After Market Close Aug 19 2014
Urologix to Host Its Fiscal Year 2014 Fourth Quarter Conference Call Aug 13 2014
Urologix to Host Its Fiscal Year 2014 Fourth Quarter Conference Call Aug 13 2014
UROLOGIX INC Financials May 23 2014
UROLOGIX INC Files SEC form 10-Q, Quarterly Report May 14 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition May 07 2014
Urologix, Inc. Earnings Call scheduled for 5:00 pm ET today May 06 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Apr 16 2014
Urologix invited to participate in “The 2014 Scottsdale Summit” presented by the Rush University... Mar 27 2014
UROLOGIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Mar 27 2014
UROLOGIX INC Files SEC form 10-Q, Quarterly Report Feb 13 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 05 2014
Urologix's CEO Discusses F2Q 2014 Results - Earnings Call Transcript Feb 04 2014
Urologix Reports Fiscal Year 2014 Second Quarter Results Feb 04 2014
Urologix Secures Extension of Credit Facility Feb 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide